TrioBiotics Pharma AG
Triton BioPharma to be profiled on CNBC Europe
Triton Biopharma AG / Miscellaneous Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Zug, Switzerland - February 27th 2009 - TRITON BIOPHARMA AG (Frankfurt: 4ON) today announced that the company will be profiled in an interview by Business News Television scheduled to air on CNBC Europe on March 2nd and March 10th, 2009 during the Squawk Box Europe/Power Lunch between 11am and 1pm GMT. The broadcast identifies exciting and innovative companies in the field of science and technology, highlighting Triton's unique pharmaceutical development pipeline and aggressive management team. Focused on the biodiversity of marine natural products as a source of drug leads, the interview provides an overview of Triton's business model, targeted areas of research and its commitment to collaboration with leading academic institutions and investigators worldwide. 'Triton was established as a vehicle to support commercialization of valuable drug discovery and preclinical research conducted by top research facilities and investigators worldwide', said Angelo Boujos, Chairman and CEO of Triton BioPharma AG. Mr. Boujos continued, 'We believe that Triton is positioned perfectly to turn the recent economic downturn into tremendous opportunities to add value to its impressive product development pipeline.' About Triton BioPharma AG Triton BioPharma AG is a holding company and is only active through its wholly-owned subsidiaries, Triton BioPharma SARL and Triton BioPharma LLC. These subsidiary companies are responsible for all of Triton's biotechnology operations and R&D activities in the discovery, development, and commercialization of novel drug leads from marine sources for the global market. With a commitment to cooperation in innovation, Triton brings together a significant network of international collaborators, consultants and industry specialists in the areas of microbiology, pharmacology, synthetic and organic chemistry, marine natural products and biochemistry. Accessing this critical mass of scientific experts and utilizing research facilities worldwide is a principal component of its drug discovery and development strategy. Triton's current pipeline includes advanced preclinical candidates in the treatment of neuropsychiatric disorders, including depression and anxiety, inflammation, infectious diseases and cancer. The company was founded in 2008 and has its corporate office in Toronto, Canada. For more information, visit www.tritonbiopharma.com. 27.02.2009 Financial News transmitted by DGAP ----------------------------------------------------------------------
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found